1型糖尿病高危儿童中家族史与早期生长对β细胞自身免疫风险的影响
本研究为TRIGR试验的二次分析,纳入2074名有一级亲属患1型糖尿病且携带HLA易感基因的儿童,比较母系、父系或同胞患病对多重β细胞自身抗体出现的影响。结果显示,母系患病儿童发生多重自身抗体的风险低于同胞患病儿童(HR 0.54),父系患病与同胞患病风险无显著差异;出生后24个月身高增长速度与多重自身抗体风险独立相关(HR 1.31)。
要点
- 母系1型糖尿病后代多重β细胞自身抗体风险显著低于同胞患病后代。
- 父系患病与同胞患病后代风险无显著差异。
- 出生后24个月身高增长速度较快与多重自身抗体风险升高独立相关。
核心结论
- 母系1型糖尿病后代发生多重β细胞自身抗体的风险较低。
- 全组中该风险与出生体重无关,但身高增长速度较快者风险更高。
- 父系1型糖尿病相关风险与出生体重或早期生长差异无关。
研究设计与样本
- TRIGR试验的二次分析,纳入2074名有一级亲属患1型糖尿病且HLA易感的儿童。
- 比较母系、父系或同胞患病与β细胞自身抗体出现的关系。
主要发现
- 277名(13%)儿童出现多重自身抗体(5种中≥2种)。
- 母系、父系、同胞患病后代多重自身抗体比例分别为10%、16%、18%(p < 0.001)。
- 与同胞患病后代相比,母系患病后代多重自身免疫HR为0.54(95% CI 0.39, 0.75,p < 0.001),父系患病后代HR为0.81(95% CI 0.59, 1.11,p = 0.19)。
- 三组间首次自身抗体出现时间相似。
- 出生后24个月身高增长速度(z评分/年)与多重抗体风险独立相关(HR 1.31 [95% CI 1.01, 1.70],p = 0.04)。
关键数值与推荐
- 多重自身抗体定义为5种检测抗体中≥2种阳性。
- 母系患病后代多重自身免疫风险显著低于同胞患病后代(HR 0.54)。
- 出生后24个月身高增长速度每增加1个z评分/年,多重抗体风险HR为1.31。
临床怎么用
- 评估1型糖尿病高危儿童风险时,需考虑家族史类型(母系、父系或同胞患病)。
- 母系患病后代的自身免疫风险相对较低,可据此进行风险分层咨询。
- 出生后早期身高增长速度较快的儿童可能需更密切的自身抗体监测。
局限性
- 本研究为TRIGR试验的二次分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this work was to examine the relationship between family history of type 1 diabetes, birthweight, growth during the first 2 years and development of multiple beta cell autoantibodies in children with a first-degree relative with type 1 diabetes and HLA-conferred disease susceptibility. METHODS: In a secondary analysis of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR), clinical characteristics and development of beta cell autoantibodies were compared in relation to family history of type 1 diabetes (mother vs father vs sibling) in 2074 children from families with a single affected family member. RESULTS: Multiple autoantibodies (≥2 of 5 measured) developed in 277 (13%) children: 107 (10%), 114 (16%) and 56 (18%) born with a mother, father or sibling with type 1 diabetes, respectively (p < 0.001). The HR for time to multiple autoimmunity was 0.54 (95% CI 0.39, 0.75) in offspring of affected mothers (n = 107/1046, p < 0.001) and 0.81 (95% CI 0.59, 1.11) (n = 114/722, p = 0.19) in offspring of affected fathers, compared with participants with a sibling with type 1 diabetes (comparator group n = 56/306). The time to the first autoantibody present (to insulin, GAD, tyrosine phosphatase-related insulinoma-associated 2 molecules, islet cell or zinc transporter 8) was similar in the three groups. Height velocity (z score/year) in the first 24 months was independently associated with developing multiple antibodies in the total cohort (HR 1.31 [95% CI 1.01, 1.70], p = 0.04). A higher birthweight in children born to an affected mother vs affected father or an affected sibling was not related to the risk of multiple autoimmunity. CONCLUSIONS/INTERPRETATION: The risk of developing multiple autoantibodies was lower in children with maternal type 1 diabetes. For the whole group, this risk of developing multiple autoantibodies was independent of birthweight but was greater in those with increased height velocity during the first 2 years of life. However, the risk associated with paternal type 1 diabetes was not linked to differences in birthweight or early growth. TRIAL REGISTRATION: ClinicalTrials.gov NCT00179777 Graphical abstract.
引用
- Pacaud D, Nucci AM, Cuthbertson D, et al. Association between family history, early growth and the risk of beta cell autoimmunity in children at risk for type 1 diabetes. Diabetologia. 2020. PMID: 33026463. doi:10.1007/s00125-020-05287-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。